Document is current
Any future updates will be listed below
-
Authors
Rinaldetti, S. https://orcid.org/0000-0003-1053-3831
Chepeleva, M. https://orcid.org/0000-0003-3036-4916
Hedblom, A.
Sticht, C. https://orcid.org/0000-0003-3596-6094
Muciek, M.
Panayiotidis, P.
Richter, J. https://orcid.org/0000-0002-0374-6823
Olsson-Strömberg, U.
Nowak, D. https://orcid.org/0000-0001-7130-7921
Nowak, V.
Ljungman, P. https://orcid.org/0000-0002-8281-3245
von Bubnoff, N.
Lotfi, K. https://orcid.org/0000-0001-5797-7232
Stenke, L.
Brümmendorf, T. H. https://orcid.org/0000-0002-9677-3723
Hjorth-Hansen, H. https://orcid.org/0000-0002-2670-5696
Gedde-Dahl, T.
Majeed, W.
Burchert, A. https://orcid.org/0000-0002-8411-8844
Nazarov, P. V. https://orcid.org/0000-0003-3443-0298
Felde, E.
Tarnopolscaia, I.
Hoelting, C.
Fabarius, A. https://orcid.org/0000-0001-5976-2876
Hofmann, W.-K.
Mahon, F.-X.
Saussele, S. https://orcid.org/0000-0003-0357-5785
Pfirrmann, M. https://orcid.org/0000-0002-8948-0690
-
Funding
Funding for this research was provided by:
Novartis | Novartis Pharma
Research funded by novartis
Fonds National de la Recherche Luxembourg (PRIDE21/16763386/CANBIO2)
- License Information
-
More Information
Article History
Received: 28 November 2025
Revised: 22 April 2026
Accepted: 22 May 2026
First Online: 18 June 2026
Competing interests
: This research was funded by Novartis. NvB: Honoraria: Blueprint Medicines, Novartis, GlaxoSmithKline, Bristol Myers Squibb/Pfizer, MSD Oncology; Travel, Accommodations, Expenses: Janssen Oncology.
: All methods were performed in accordance with the relevant guidelines and regulations. In accordance with the Declaration of Helsinki, written informed consent was obtained from all patients. The EURO-SKI protocol (EURO-SKI V2.1) obtained approval from the ethics committee (Medical Faculty Mannheim) under the reference number 2012-247AWB-MA.
